Dr. Yang Liang 梁洋
Chief Physician, Research Professor
Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized chemotherapy and precision targeted therapy for adult and pediatric hematologic malignancies, including leukemia, myelodysplastic syndromes, myeloproliferative disorders, lymphoma, and myeloma.
Dr. Liang completed a postdoctoral fellowship in adult hematology at the Yale University School of Medicine Cancer Center. Research focuses on the pathogenesis and targeted therapy of myelodysplastic syndromes and myeloproliferative disorders. Clinical work involves optimizing international standardized chemotherapy protocols for local treatment of hematologic malignancies.
Professional roles
- Member, American Society of Hematology
- Vice Chair, Precision Medicine Division, Wu Jieping Medical Foundation
- President-Elect, Hematology Branch, Asia-Pacific Medical Student Biological Immunology Society
- Member, Plasma Cell Disease Group, 11th Committee of Hematology Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Liang Yang). Papers usually list the name as Yang Liang or Liang Y.
Selected publications
98 papers on PubMed matched by name and affiliation; 44 as first or senior author since 2016. Most recent first- or senior-author papers:
- Leukemia, 2026 (senior author): Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies. PubMed 42957753
- Leukemia, 2026 (senior author): Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies. PubMed 42062556
- Cancer Med, 2026 (senior author): Adverse Effects of Low Serum HDL-C Levels on Prognosis and Tumor Immune Microenvironment in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia. PubMed 41981359
- N Engl J Med, 2025 (senior author): Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. PubMed 41337730
- J Inflamm Res, 2025 (senior author): Glasgow Prognostic Score Serves as a Prognostic Factor of Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma. PubMed 40969302
- J Immunother Cancer, 2025 (senior author): Mapping the cancer vaccine landscape. PubMed 40940135
- Cancer Cell Int, 2025 (senior author): Predicting survival of persons with newly-diagnosed multiple myeloma. PubMed 40783547
- Acta Haematol, 2025 (first author): A Prognostic Survival Model Based on Endocrine-Related Gene Expression in Acute Myelogenous Leukemia. PubMed 39809225
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion